je.st
news
Tag: antibody
Prometheus Launches New Adalimumab Drug And Antibody Levels Monitoring Test
2013-05-01 06:54:34| drugdiscoveryonline News Articles
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the US market launch of its proprietary new test, PROMETHEUS®Anser™ ADA
Tags: test
levels
drug
monitoring
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
2013-04-24 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is Mercks investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for the treatment of patients with advanced melanoma, and other tumor types. Language: English Contact HTML: MerckMedia:Caroline Lapppetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
therapy
announces
designation
APO-T And LinXis Announce Antibody Drug Conjugate Option To In-License Agreement
2013-03-22 09:08:00| drugdiscoveryonline News Articles
APO-T B.V. and LinXis B.V., both privately owned oncology companies, announced recently that LinXis has granted APO-T an exclusive worldwide license for the development and commercialization of fully-human antibody-drug-conjugates using APO-T’s MAGE-HLA targeted antibodies and LinXis’ unique LX linker technology
Tags: agreement
option
drug
announce